<DOC>
	<DOCNO>NCT01873170</DOCNO>
	<brief_summary>This study do understand use birth control cause change immune cell within reproductive tract ( include cervix line uterus ) healthy woman . Immune cell important help prevent infection start help fight infection start . Immune cell also type cell HIV ( human immunodeficiency virus ) infect understand help good understand prevent spread HIV . Immune cell study reproductive tract woman want start use one follow contraceptive : oral contraceptive pill ( COC ) , Depo-Provera ( DMPA ) , levonorgestrel IUD ( Mirena® ) , copper IUD ( ParaGard® ) , etonogestrel subdermal implant ( Nexplanon® ) .Immune cell also study reproductive tract woman use birth control risk pregnancy comparison .</brief_summary>
	<brief_title>Quantification Immune Cells Women Using Contraception ( CHIC II )</brief_title>
	<detailed_description />
	<mesh_term>Copper</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<mesh_term>Etonogestrel</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>1 . Age 18 34 year ( inclusive ) screen 2 . Nonpregnant woman general good health determine site clinician 3 . Premenopausal history regular menstrual cycle ( regular cycle define occur every 2135 day use hormones variation typical cycle length 5 day ) 4 . Women enrol control group : Regular consistent condom use , prior surgical sterilization participant sexual partner , heterosexually abstinent entire study participation 5 . Able willing provide write informed consent screen take part study . Including willingness undergo studyrelated assessment follow studyrelated procedure 6 . Able willing provide adequate locator information 7 . HIVuninfected base test perform study staff screening ( per HIV test algorithm Appendices I ) 8 . At screen enrollment , agree participate research study involve drug , medical device , vaginal product enrol trial 1 . Use hormonal intrauterine contraceptive method within 30 day enrollment 2 . Use DMPA within 10 month enrollment 3 . Pregnancy breastfeed within 60 day enrollment 4 . Surgical procedure involve pelvis 30 day prior enrollment ( include dilation curettage , cryosurgery biopsy vagina , vulva , cervix , endometrium ) 5 . Internal vaginal use device ( include sex toy , cervical cap , diaphragm , menstrual collection device , pessary ; excludes tampon condom ) product ( include N9 , microbicide , douche , antifungal , steroid , hormone ) 30 day prior enrollment 6 . New sexual partner within 90 day enrollment 7 . Urogenital infection suspect infection within 30 day enrollment include : symptomatic candidiasis , trichomonas vaginalis , symptomatic bacterial vaginosis ; cervical infection , include N. gonorrhea , C. trachomatis , mucopurulent cervicitis ; syphilis ; HSV lesion , sore ( Note : seropositive HSV without active lesion exclude ) ; acute pelvic inflammatory disease ; urinary tract infection ; recent exposure partner GC , CT , Trichomonas , syphilis , NGU 8 . Any history immunosuppression ( include diabetes , HIV infection , chronic steroid use ) 9 . Antibiotic antifungal therapy ( vaginal systemic ) within 30 day enrollment 10 . Menses vaginal bleeding time Enrollment* ( *Women vaginal bleeding schedule Enrollment Visit may return different date reexamine possibly enrol provide still within 90day screen window meet criterion ) . 11 . Vaginal anal intercourse within 36 hour prior enrollment 12 . Heterosexual intercourse since last menses place participant risk pregnancy ( without condom use sterilization least one partner ) 13 . History hysterectomy 14 . History malignancy within pelvis ( include uterus , cervix , vagina , vulva ) 15 . Contraindication , allergy intolerance use contraceptive desire participant 16 . Any condition , opinion Investigator , would preclude provision consent , make participation study unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>34 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>immune cell</keyword>
	<keyword>contraception</keyword>
	<keyword>intrauterine device</keyword>
	<keyword>IUD</keyword>
	<keyword>copper</keyword>
	<keyword>microflora</keyword>
	<keyword>DMPA</keyword>
	<keyword>etonogestrel</keyword>
	<keyword>subdermal implant</keyword>
</DOC>